Development of new anticancer thiadiazole-sulfonamides as dual EGFR/carbonic anhydrase inhibitors
Compound <b>14</b> represents a promising dual EGFR/CA-IX inhibitor with selective anticancer activity. Further <i>in vivo</i> studies are warranted.
Authors
- Ibrahim H. Eissa (ORCID: https://orcid.org/0000-0002-6955-2263)
- Bshra Ali A. Alsfouk (ORCID: https://orcid.org/0000-0001-6489-6035)
- Walid E. Elgammal (ORCID: https://orcid.org/0000-0002-5982-5635)
- Hazem Elkady (ORCID: https://orcid.org/0000-0003-0893-6703)
- Eslam B. Elkaeed (ORCID: https://orcid.org/0000-0002-2546-8035)
- Dalal Z. Husein (ORCID: https://orcid.org/0000-0001-7552-0914)
- Hazem A. Mahdy
- Ahmed M. Metwaly (ORCID: https://orcid.org/0000-0001-8566-1980)
- Fatma G. Amin (ORCID: https://orcid.org/0000-0003-2615-7375)
- Ibrahim M. Ibrahim (ORCID: https://orcid.org/0009-0005-1699-848X)
- Hany S. Elshennawy
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Cairo University (EG)
- Nile Valley University (SD)
- Al-Azhar University (ID)
- New Valley University
- Almaarefa University
- Alexandria University (EG)
Publication Details
- Journal
- Future Medicinal Chemistry
- Published
- 2025-05-03
- DOI
- https://doi.org/10.1080/17568919.2025.2498879
- Citations
- 7
- Primary Topic
- Enzyme function and inhibition
- Type
- article
- Field-Weighted Citation Impact
- 5.64
Funders
- AlMaarefa University
- Princess Nourah Bint Abdulrahman University